Literature DB >> 22107964

Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice.

Vladimir N Anisimov1, Mark A Zabezhinski, Irina G Popovich, Tatiana S Piskunova, Anna V Semenchenko, Margarita L Tyndyk, Maria N Yurova, Svetlana V Rosenfeld, Mikhail V Blagosklonny.   

Abstract

The nutrient-sensing TOR (target of rapamycin) pathway is involved in cellular and organismal aging. Rapamycin, an inhibitor of TOR, extends lifespan in yeast, fruit flies and genetically heterogeneous mice. Here, we demonstrate that lifelong administration of rapamycin extends lifespan in female 129/Sv mice characterized by normal mean lifespan of 2 y. Importantly, rapamycin was administrated intermittently (2 weeks per month) starting from the age of 2 mo. Rapamycin inhibited age-related weight gain, decreased aging rate, increased lifespan (especially in the last survivors) and delayed spontaneous cancer. 22.9% of rapamycin-treated mice survived the age of death of the last mouse in control group. Thus we demonstrated for the first time in normal inbred mice that lifespan can be extended by rapamycin. This opens an avenue to develop optimal doses and schedules of rapamycin as an anti-aging modality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22107964     DOI: 10.4161/cc.10.24.18486

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  185 in total

1.  Chronic rapamycin treatment or lack of S6K1 does not reduce ribosome activity in vivo.

Authors:  Michael G Garelick; Vivian L Mackay; Aya Yanagida; Emmeline C Academia; Katherine H Schreiber; Warren C Ladiges; Brian K Kennedy
Journal:  Cell Cycle       Date:  2013-07-01       Impact factor: 4.534

Review 2.  mTOR is a key modulator of ageing and age-related disease.

Authors:  Simon C Johnson; Peter S Rabinovitch; Matt Kaeberlein
Journal:  Nature       Date:  2013-01-17       Impact factor: 49.962

3.  Erlotinib antagonizes ABC transporters in acute myeloid leukemia.

Authors:  Elodie Lainey; Marie Sébert; Sylvain Thépot; Marie Scoazec; Cyrielle Bouteloup; Carole Leroy; Stéphane De Botton; Lorenzo Galluzzi; Pierre Fenaux; Guido Kroemer
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

4.  Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.

Authors:  Irina G Popovich; Vladimir N Anisimov; Mark A Zabezhinski; Anna V Semenchenko; Margarita L Tyndyk; Maria N Yurova; Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

5.  Comparison of rapamycin schedules in mice on high-fat diet.

Authors:  Olga V Leontieva; Geraldine M Paszkiewicz; Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  mTORC1 and p53: clash of the gods?

Authors:  Paul Hasty; Zelton Dave Sharp; Tyler J Curiel; Judith Campisi
Journal:  Cell Cycle       Date:  2013-01-01       Impact factor: 4.534

Review 7.  Rapalogs and mTOR inhibitors as anti-aging therapeutics.

Authors:  Dudley W Lamming; Lan Ye; David M Sabatini; Joseph A Baur
Journal:  J Clin Invest       Date:  2013-03-01       Impact factor: 14.808

Review 8.  Metabolic Stress, Autophagy, and Cardiovascular Aging: from Pathophysiology to Therapeutics.

Authors:  Jun Ren; James R Sowers; Yingmei Zhang
Journal:  Trends Endocrinol Metab       Date:  2018-08-22       Impact factor: 12.015

Review 9.  Targeting Autophagy in Aging and Aging-Related Cardiovascular Diseases.

Authors:  Jun Ren; Yingmei Zhang
Journal:  Trends Pharmacol Sci       Date:  2018-10-26       Impact factor: 14.819

10.  Hypoxia suppresses conversion from proliferative arrest to cellular senescence.

Authors:  Olga V Leontieva; Venkatesh Natarajan; Zoya N Demidenko; Lyudmila G Burdelya; Andrei V Gudkov; Mikhail V Blagosklonny
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.